MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-19-2022
Calliditas Therapeutics AB (publ) Operating Expenses 2011-2026 | CALT
Annual Operating Expenses Calliditas Therapeutics AB (publ)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 213 M | 133 M | 84.7 M | 56.5 M | 51.4 M | - | - | - | - |
All numbers in SEK currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 213 M | 51.4 M | 108 M |
Operating Expenses of other stocks in the Drug manufacturers industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
40.3 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
38.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
213 M | - | - | $ 754 M | USA |
 |
Assertio Holdings
ASRT
|
133 M | $ 19.21 | -3.37 % | $ 123 M | USA |
 |
Canopy Growth Corporation
CGC
|
197 M | $ 1.0 | 2.63 % | $ 108 M |  Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
196 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
154 M | $ 2.53 | 0.8 % | $ 1.33 B | Canada |
 |
Aurora Cannabis
ACB
|
183 M | $ 3.44 | 2.69 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
512 M | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
30.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
71.8 M | - | - | $ 142 M | USA |
 |
China Pharma Holdings
CPHI
|
3.11 M | $ 0.63 | -1.56 % | $ 2.7 M |  China |
 |
Athenex
ATNX
|
96.7 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
113 M | - | -39.89 % | $ 27.7 M | USA |
 |
DURECT Corporation
DRRX
|
44.6 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
558 M | $ 8.23 | -1.79 % | $ 421 M | USA |
 |
Evoke Pharma
EVOK
|
12.6 M | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
106 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
35.2 M | $ 3.17 | 2.26 % | $ 44.6 M | USA |
 |
Endo International plc
ENDP
|
763 M | - | - | $ 28.9 M |  Irlanda |
 |
Bausch Health Companies
BHC
|
4.96 B | $ 5.35 | -4.12 % | $ 1.95 B | Canada |
 |
Harrow Health
HROW
|
174 M | $ 35.31 | -0.34 % | $ 1.3 B | USA |
 |
Jupiter Wellness
JUPW
|
12.5 M | - | - | $ 33.6 M | USA |
 |
Evolus
EOLS
|
107 M | $ 4.03 | -6.5 % | $ 260 M | USA |
 |
Lannett Company
LCI
|
209 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
103 M | - | - | $ 193 M | Canada |
 |
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | USA |
 |
Organogenesis Holdings
ORGO
|
368 M | $ 2.24 | -3.03 % | $ 295 M | USA |
 |
Pacira BioSciences
PCRX
|
279 M | $ 22.7 | -0.39 % | $ 1.05 B | USA |
 |
PetIQ
PETQ
|
138 M | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
44.2 M | - | -27.8 % | $ 2.56 M | USA |
 |
Perrigo Company plc
PRGO
|
2.62 B | $ 10.85 | -1.36 % | $ 1.5 B | USA |
 |
ProPhase Labs
PRPH
|
47.1 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
304 M | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
59.1 M | $ 6.99 | -1.55 % | $ 276 M | USA |
 |
Recro Pharma
REPH
|
22.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
Rockwell Medical
RMTI
|
31.1 M | $ 0.96 | 2.54 % | $ 34.5 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
9.18 M | $ 2.37 | -2.47 % | $ 2.94 M | USA |
 |
Solid Biosciences
SLDB
|
179 M | $ 7.49 | 1.49 % | $ 655 M | USA |
 |
Viatris
VTRS
|
5.67 B | $ 13.44 | -1.39 % | $ 16.1 B | USA |
 |
cbdMD
YCBD
|
28.9 M | $ 0.73 | 2.37 % | $ 3.15 M | USA |
 |
Zomedica Corp.
ZOM
|
14.1 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
35.3 M | - | - | $ 55.5 M | USA |
 |
SCYNEXIS
SCYX
|
36.7 M | $ 0.89 | -0.05 % | $ 44.4 M | USA |
 |
Tricida
TCDA
|
153 M | - | - | $ 3.25 M | USA |
 |
OrganiGram Holdings
OGI
|
41.4 M | $ 1.38 | 2.99 % | $ 402 M | Canada |
 |
TherapeuticsMD
TXMD
|
7.41 M | $ 2.0 | - | $ 23.1 M | USA |
 |
Sundial Growers
SNDL
|
102 K | $ 1.36 | 2.26 % | $ 3.37 M | Canada |
 |
Tilray
TLRY
|
1.52 B | $ 6.55 | 6.68 % | $ 4.05 B | Canada |